Date: 2015-04-08
Type of information: R&D agreement
Compound: AAV vectors
Company: RegenXBio (USA - MD) University of Pennsylvania (PA) University of Minnesota (MN)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: R&D licensing
Action mechanism: gene therapy
Disease: Hurler syndrome or mucopolysaccharidosis type I (MPS I), Hunter syndrome or mucopolysaccharidosis type II (MPS II)
Details: * On April 8, 2015, RegenXBio, a leading biotechnology company in gene therapy, announced that it has entered into separate license and research agreements with the University of Pennsylvania (Penn) and University of Minnesota (U of M) related to the delivery of AAV vectors for the treatment of MPS I and MPS II, also known as Hurler syndrome and Hunter syndrome, respectively. These agreements provide RegenXBio with exclusive access to key technologies and resources that the Company plans to apply in the development of first-in-class treatments for MPS I and MPS II using its proprietary NAV® Technology.
Financial terms:
Latest news:
